FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Find answers to all your questions on live JUBILANT message board: Is JUBILANT buy or sell? Should I buy JUBILANT shares? Why are JUBILANT shares falling? Should I invest in JUBILANT stock?
forum
JUBILANT Share Price Discussion
Jubilant Life Sciences Ltd.
NSE: JUBILANT | BSE: 530019 | ISIN: INE700A01033 | Sector: Pharmaceuticals and health care
N
Reputation: 4,625 • Jun 23 10:36 AM
Dassault Systèmes demonstrates innovations for the life sciences industry in India
The event focused on transforming and digitalizing the life sciences industry in India, which is undergoing core shifts in business processes and manufacturing operations to make it more agile and adaptable.
The event focused on transforming and digitalizing the life sciences industry in India, which is undergoing core shifts in business processes and manufacturing operations to make it more agile and adaptable.
The Economic Times
Like
Reply
NSE:JUBILANT price when posted: 672.5
Recent posts in JUBILANT
N
Reputation: 4,625 • Jul 31 1:53 AM
Remdesivir shortage to ease in August as existing suppliers boost capacity, new manufacturers enter
Around 8 lakh doses are expected to be available in the country in August as new manufacturers are getting ready to enter the market with their generic versions.
Around 8 lakh doses are expected to be available in the country in August as new manufacturers are getting ready to enter the market with their generic versions.
Moneycontrol
Like
Reply
N
Reputation: 4,625 • Jul 30 2:28 AM
Trade Spotlight: Dr Reddy’s, IndusInd Bank, Nestle, Maruti and Jubilant Life in focus
Indian market witnessed profit-taking at higher levels on Wednesday and the trend is likely to remain volatile on Thursday as well ahead of June F&O expiry.
Indian market witnessed profit-taking at higher levels on Wednesday and the trend is likely to remain volatile on Thursday as well ahead of June F&O expiry.
Moneycontrol
Like
Reply
N
Reputation: 4,625 • Jul 29 3:08 AM
Dr Reddy's expects to launch Remdesivir in August
On another antivral Favipiravir, which is prescribed for mild COVID-19 cases, Dr Reddy's said it will be going ahead with the product, despite Glenmark's clinical trial data hasn't been statistically significant.
On another antivral Favipiravir, which is prescribed for mild COVID-19 cases, Dr Reddy's said it will be going ahead with the product, despite Glenmark's clinical trial data hasn't been statistically significant.
Moneycontrol
Like
Reply